Full history for every metric is available with a Kvantra account
Adamas Pharmaceuticals, Inc. (ADMS)
Key financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 1 | 1 | 34 | 55 | 74 | 88 |
| Operating profit | $m | -44 | -39 | |||||
| Net profit | $m | -52 | -60 | -89 | -131 | -105 | -57 | -63 |
| EPS reported | $ | -1.63 | -1.70 | |||||
| Operating cashflow per share | $ | -1.44 | -1.44 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.44 | -1.44 | |||||
| Free cash flow | $m | -51 | -47 | |||||
| Net debt | $m | 47 | 46 | |||||
| Book value equity | $m | -50 | -22 | |||||
| Book value per share | $ | -1.42 | -0.47 | |||||
| Number of shares | m | 35.17 | 45.62 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -3.05 | -17.36 | |||||
| P/S LTM | x | 2.05 | 4.25 | |||||
| P/FCF LTM | x | -3.00 | -8.01 | |||||
| EV/EBITDA LTM | x | -4.86 | -11.07 | |||||
| EV/Sales LTM | x | 2.83 | 4.77 | |||||
| Earnings Yield LTM | % | -37.70% | -19.86% | |||||
| FCF Yield | % | -33.30% | -12.48% | |||||
| Quality | ||||||||
| ROE | % | 114.86% | 225.69% | |||||
| ROIC | % | -49.72% | -49.72% | |||||
| Operating margin | % | -59.31% | -59.31% | |||||
| Gross margin | % | 97.26% | 97.26% | |||||
| FCF/Sales | % | -68.10% | -68.10% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +36.28% | +26.35% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.39 | -0.35 | |||||
| Net Debt/EBITDA | x | -1.35 | -1.35 | |||||
| EBIT/Net interest | x | -3.34 | -3.34 | |||||
| Net debt/market cap | % | 30.60% | 12.25% | |||||
| Net debt/Equity | x | -0.93 | -2.13 | |||||
| Gross debt/equity | x | -2.60 | -6.21 | |||||
Company overview
Adamas Pharmaceuticals, Inc. is focused on the research, development, and commercialization of therapeutic solutions for individuals in the United States suffering from chronic neurological conditions. The company's marketed products include GOCOVRI, an extended-release capsule designed to treat dyskinesia in Parkinson's disease patients who are undergoing levodopa-based therapy, with or without other dopaminergic medications. Additionally, they provide Namzaric capsules, a combination of extended-release memantine hydrochloride and donepezil hydrochloride, used for managing moderate to severe Alzheimer's-type dementia. In its development pipeline, Adamas is progressing ADS-5102, which is currently undergoing Phase III clinical trials to address walking difficulties in patients with multiple sclerosis, among other potential applications. The firm has also completed two Phase I studies for ADS-4101, a candidate treatment for partial onset seizures in epilepsy patients. Founded in 2000, the company initially operated as NeuroMolecular Pharmaceuticals, Inc. before changing its name to Adamas Pharmaceuticals, Inc. in July 2007. Its corporate headquarters are located in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Adamas Pharmaceuticals, Inc. (ADMS)
Adamas Pharmaceuticals, Inc. is focused on the research, development, and commercialization of therapeutic solutions for individuals in the United States suffering from chronic neurological conditions. The company's marketed products include GOCOVRI, an extended-release capsule designed to treat dyskinesia in Parkinson's disease patients who are undergoing levodopa-based therapy, with or without other dopaminergic medications. Additionally, they provide Namzaric capsules, a combination of extended-release memantine hydrochloride and donepezil hydrochloride, used for managing moderate to severe Alzheimer's-type dementia. In its development pipeline, Adamas is progressing ADS-5102, which is currently undergoing Phase III clinical trials to address walking difficulties in patients with multiple sclerosis, among other potential applications. The firm has also completed two Phase I studies for ADS-4101, a candidate treatment for partial onset seizures in epilepsy patients. Founded in 2000, the company initially operated as NeuroMolecular Pharmaceuticals, Inc. before changing its name to Adamas Pharmaceuticals, Inc. in July 2007. Its corporate headquarters are located in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free